RECRUITINGOBSERVATIONAL
Cohort of IPF Patients Experiencing an Exacerbation
Pulmonary Fibrosis Biomarkers During Exacerbation
About This Trial
Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years. In the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.
Who May Be Eligible (Plain English)
Who May Qualify:
- Admitted with an increase in respiratory symptoms
- Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA
- Age at least 18 years
Who Should NOT Join This Trial:
- Unable to provide willing to sign a consent form
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Admitted with an increase in respiratory symptoms
* Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA
* Age at least 18 years
Exclusion Criteria:
* Unable to provide informed consent
Locations (1)
Herlev and Gentofte Hospital
Hellerup, Copenhagen, Denmark